With support from The Medulloblastoma Initiative, these labs are focusing on:
1
Using new technologies (including single cell sequencing and proteomics) to discover the origins/drivers of medulloblastoma and to identify novel targets for molecularly-targeted therapy.
2
Discovering novel neoantigens that can be targeted by the immune system.
3
Developing new, more informative mouse models (including humanized-models) of Group 4 medulloblastoma to expedite development of therapies targeting the novel biologic underpinnings being discovered.
4
Using these models to understand the interplay between molecular determinants and the immune environment in Group 4 medulloblastoma, so as to better design immunologic approaches.